Le Lézard
Classified in: Health, Science and technology, Business
Subject: FINANCING AGREEMENTS

Derm-Biome Pharmaceuticals and TransBIOtech awarded $450,000 Applied Research and Development (ARD) grant funding


VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a Vancouver based biopharmaceutical company focused on skin health and healthy aging, is pleased to announce that, in partnership with TransBIOtech (Quebec), is being awarded an Applied Research and Development (ARD) grant via the College and Community Innovation (CCI) program administered through the Natural Sciences and Engineering Council of Canada in collaboration with the Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research.

Derm-Biome has developed novel compounds with wide ranging pharmacological activities. The grant, which spans 3 years and totals $450,000, will support Derm-Biome's preclinical research activities, with a focus on inflammatory diseases and healthy aging.

Frédéric Couture, Principal Investigator and Head of Pharmaceutical Sciences at TransBIOtech: "This is very exciting news. We are happy to pursue this collaboration with Derm-Biome and help them propel their pipeline closer to new treatments. I believe that, along with co-PIs Dr Sarah Paris-Robidas and Dr Carole-Ann Huppé, our expertise in preclinical pharmacology in synergy with Derm-Biome's scientific team will accelerate future efficacy validation of their products and provide them with the key demonstrations needed for upcoming clinical trial applications."

Derm-Biome CEO Gordon Eberwein: "We are very pleased to have been awarded this Applied Research and Development grant and very much look forward to our continued working relationship with TransBIOtech in helping advance our exciting preclinical pipeline."

About Derm-Biome Pharmaceuticals, Inc

Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health and healthy aging. We are developing novel topical therapies for inflammatory skin diseases and precancerous skin conditions/non-melanoma skin cancers that are both highly effective and well tolerated by skin.

Contact
Investor Inquiries:
Gordon Eberwein
[email protected]
https://derm-biomepharmaceuticals.com/



These press releases may also interest you

at 19:30
Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP agilon health, inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors to Contact the Firm (AGL)
The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against agilon health, inc. ("agilon" or the "Company").  This action, captioned Hope v. agilon health, inc., et...

at 18:00
bioLytical Laboratories Inc. Announces Launch of its INSTI® HCV Antibody Test for Professional Use in Australia
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market.  The INSTI Hepatitis C (HCV) Antibody Test is now included in the Australian Register of Therapeutic Goods (ARTG...

at 17:20
New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or...

at 14:15
New Phase 2a Clinical Trial Results Demonstrate Endeavor BioMedicines' ENV-101 Improved Lung Function and Reversed Key Measures of Lung Fibrosis in Patients With Idiopathic Pulmonary Fibrosis
Endeavor BioMedicines, a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced results from a completed Phase 2a clinical trial...

at 12:20
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024 International Conference that is taking place May 17-22, 2024, in San Diego,...

at 12:18
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

More news about Health...


News published on and distributed by: